With Mahnu Davar, Kathleen Harris, Tirzah S. Lollar, Jacqueline Mulryne, Eliseo R. Puig, John Tan
he life sciences industry has long been a focus of anti-corruption enforcement, and changing models for global clinical research have made anti-corruption a critical risk area for research-based